Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/02/04 02:37:03」(JST)

wiki en

Nicergoline (INN, marketed under the trade name Sermion) is an ergot derivative used to treat senile dementia and other disorders with vascular origins. It has been found to increase mental agility and enhance clarity and perception. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.

It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascular migraines, and retinopathy.

Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.^[1]

Clinical uses

Nicerogline is used in the following cases:

Acute and chronic cerebral metabolic-vascular disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism, transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular disorders (organic and functional arteriopathies of the limbs), Raynaud’s disease and other syndromes caused by altered peripheral irrigation.
Migraines of vascular origin
Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial tension.
Corio-retinal vascular disorders: diabetic retinopathy, macular degeneration and retinal angiosclerosis
Oto-vestibular problems of a vascular nature: dizziness, auditory hallucinations, hypoacusis.

Dosages for known conditions are usually administered at 5–10 mg three times a day, however anti-aging preventative purposes may want to consider 5 mg once or twice a day more adequate.^[2]

Contraindications

Persons suffering from acute bleeding, myocardial infarction (heart conditions), hypertension, bradycardia or using alpha or beta receptor agonists should consult with their physician before use. Although toxicology studies have not shown nicergoline to have any teratogenic effect, the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.

On 28 June 2013 the European Medicines Agency recommended restricting the use of medicines containing ergot derivatives, including Nicergoline. They stated that "these medicines should no longer be used to treat several conditions involving blood circulation problems or problems with memory and sensation, or to prevent migraine headaches, since the risks are greater than the benefits in these indications. This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines." (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001832.jsp&mid=WC0b01ac058004d5c1b)

Nicergoline is considered unsafe in porphyria.^[3]

Adverse effects

The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness.^[3] At high dosages bradycardia, increased appetite, agitation, diarrhea and perspiration have been known to occur. A single case of acute interstitial nephritis has been reported.^[4]

Interactions

Nicergoline is known to enhance the cardiac depressive effects of propranolol.^[3] At high dosages, it is advisable to seek one’s physician's guidance if combining with potent vasodilators such as bromocriptine, Gingko biloba, picamilon, vinpocetine or xantinol nicotinate.

Mechanism of action

Nicergoline is an ergot alkaloid derivative that acts as a potent and selective alpha-1A adrenergic receptor antagonist.^[5] The IC₅₀ of nicergoline in vitro has been reported to be 0.2 nM.^[6] The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain.

References

^ Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". Cochrane Database Syst Rev (4): CD003159. doi:10.1002/14651858.CD003159. PMID 11687175.
^ Nicergoline drug insert, Pharmacia & Upjohn, October 2000
^ ^a ^b ^c Sweetman SC, ed. (2009). "Supplementary drugs and other substances". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2352. ISBN 978-0-85369-840-1.
^ Kim MJ, Chang JH, Lee SK, et al. (2002). "Acute interstitial nephritis due to nicergoline (Sermion)". Nephron 92 (3): 676–9. doi:10.1159/000064096. PMID 12372954.
^ Alvarez-Guerra M, Bertholom N, Garay RP (1999). "Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat". Fundam Clin Pharmacol 13 (1): 50–8. doi:10.1111/j.1472-8206.1999.tb00320.x. PMID 10027088.
^ Moretti A, Carfagna N, Caccia C, Carpentieri M (1988). "Effect of ergolines on neurotransmitter systems in the rat brain". Arch Int Pharmacodyn Ther 294: 33–45. PMID 2906797.

External links

National Electronic Library for Medicines Nicergoline for dementia and other age associated forms of cognitive impairment.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 脳血管性認知症の治療および予防 treatment and prevention of vascular dementia
2. 尿毒症性そう痒症 uremic pruritus

English Journal

Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress.

Kim EC1, Toyono T2, Berlinicke CA3, Zack DJ4, Jurkunas U5, Usui T6, Jun AS3.
Investigative ophthalmology & visual science.Invest Ophthalmol Vis Sci.2017 Feb 1;58(2):892-900. doi: 10.1167/iovs.16-20147.
PMID 28159976

The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.

Laudy AE1, Kulińska E2, Tyski S3,4.
Molecules (Basel, Switzerland).Molecules.2017 Jan 11;22(1). pii: E114. doi: 10.3390/molecules22010114.
PMID 28085074

Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen.

Sullivan KG1, Levin M1.
Journal of anatomy.J Anat.2016 Oct;229(4):483-502. doi: 10.1111/joa.12467. Epub 2016 Apr 7.
PMID 27060969

Japanese Journal

回復期リハビリテーション病棟における脳卒中後うつとアパシー

高次脳機能研究（旧失語症研究） 34(2), 193-198, 2014
NAID 130005085445

私のカルテから Nicergolineにより思考途絶様症状と脳波異常が著明に改善した器質性妄想性障害の1例

精神医学 54(10), 1047-1049, 2012-10
NAID 40019469599

症例 Nicergolineとamantadineが意欲・自発性低下改善に効果的であった右前内側視床梗塞の1例

内科 94(1), 195-199, 2004-07
NAID 40006310442

Related Pictures

★リンクテーブル★

リンク元

「ニセルゴリン」

Nicergoline
Systematic (IUPAC) name
	[(8β)-10-methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyridine-3-carboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	Not recommended;
Legal status	OTC;
Routes of; administration	Oral, IM, IV
Pharmacokinetic data
Bioavailability	<5%
Protein binding	>90%
Metabolism	Extensive first-pass metabolism
Biological half-life	13–20 hours
Identifiers
CAS Number	27848-84-6
ATC code	C04AE02
PubChem	CID 34040
DrugBank	DB00699
ChemSpider	31373
UNII	JCV8365FWN
KEGG	D01290
ChEMBL	CHEMBL1372950
Chemical data
Formula	C24H26BrN3O3
Molar mass	484.386 g/mol
	SMILES Brc1cc(cnc1)C(=O)OC[C@@H]3C[C@]4(OC)c5cccc2c5c(cn2C)C[C@H]4N(C3)C ;
	InChI InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1 ; Key:YSEXMKHXIOCEJA-FVFQAYNVSA-N ;
(verify)

　　[★]

英: nicergoline
商: サアミオン、サルモシン、サワチオン、セルファミン、ソクワール、ニセルゴリン、バソゴリンS、ヒルブリンN、マリレオンN
関: その他の循環器官用薬

[1] Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". Cochrane Database Syst Rev (4): CD003159. doi:10.1002/14651858.CD003159. PMID 11687175.

[2] Nicergoline drug insert, Pharmacia & Upjohn, October 2000

[Martindale-3] Sweetman SC, ed. (2009). "Supplementary drugs and other substances". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2352. ISBN 978-0-85369-840-1.

[4] Kim MJ, Chang JH, Lee SK, et al. (2002). "Acute interstitial nephritis due to nicergoline (Sermion)". Nephron 92 (3): 676–9. doi:10.1159/000064096. PMID 12372954.

[5] Alvarez-Guerra M, Bertholom N, Garay RP (1999). "Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat". Fundam Clin Pharmacol 13 (1): 50–8. doi:10.1111/j.1472-8206.1999.tb00320.x. PMID 10027088.

[6] Moretti A, Carfagna N, Caccia C, Carpentieri M (1988). "Effect of ergolines on neurotransmitter systems in the rat brain". Arch Int Pharmacodyn Ther 294: 33–45. PMID 2906797.

匿名

検索

案内

案内

nicergoline